سوفاكسين بي آر آر إس لقاح متلازمة الخنازير التنفسية والتناسلية الحي المضعف
Suvaxyn PRRS MLV is a modified live vaccine containing attenuated Porcine Reproductive and Respiratory Syndrome (PRRS) virus strain 96V198 (European genotype, Type 1). Indicated for active immunization of clinically healthy pigs from 1 day of age to reduce viraemia, respiratory clinical signs, and viral shedding caused by PRRS virus.
الشكل الصيدلاني
Injection
نوع المنتج
بيولوجي
الشركة المصنعة
الحجم
Vials of 10, 50, and 100 doses lyophilisate with sterile solvent
| النوع الحيواني | الجرعة | طريقة الإعطاء | المدة |
|---|---|---|---|
| Swine | Reconstitute lyophilisate with solvent and administer 2 mL intramuscularly in the neck musculature | Intramuscular (IM) | Single dose from 1 day of age; breeding gilts/sows vaccinated prior to mating |
| النوع الحيواني | اللحم (أيام) | الحليب (أيام) | البيض (أيام) |
|---|---|---|---|
| Swine | 0 |
Active immunization of clinically healthy pigs from 1 day of age to reduce viraemia and nasal shedding caused by infection with European (Type 1) strains of PRRS virus.
Reduction of lung lesions and clinical respiratory disease associated with PRRS in fattening pigs.
Do not use in PRRS-negative herds where the presence of PRRS virus has not been established.
Do not vaccinate clinically diseased pigs.
Vaccine virus may spread to in-contact pigs for several weeks following vaccination; adhere to biosecurity protocols.
Transient rise in rectal temperature (up to 1.5°C) within 24 hours of vaccination, resolving spontaneously.
Suvaxyn PRRS MLV Prescribing Information
نشرةلا توجد أمراض مرتبطة.
لا توجد بيانات
لم تتم إضافة المعلومات بعد.
لا توجد بيانات
لم تتم إضافة المعلومات بعد.
شركة مصنعة
لا توجد بدائل متاحة.